The effect of Gleason score on the predictive value of prostate-specific antigen doubling time

BJU International

Volumn 105, Issue 10, 2010, Pages 1381-1385

  Tollefson, Matthew K ^a   Blute, Michael L ^a   Rangel, Laureano J ^a   Bergstralh, Erik J ^a   Boorjian, Stephen A ^a   Karnes, R Jeffrey ^a  

^a MAYO CLINIC   (United States)

Author keywords

Doubling time; Gleason score; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE COURSE; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 77951729058     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08976.x     Document Type: Article

References (32)

1. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004 101 : 894 904
2. Sengupta S, Blute ML, Bagniewski SM et al. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. J Urol 2006 175 : 1684 1690
3. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005 294 : 440 447
4. King CR, Freedland SJ, Terris MK et al. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology 2007 69 : 732 737
5. Tollefson MK, Slezak JM, Leibovich BC, Zincke H, Blute ML. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc 2007 82 : 422 427
6. Freedland SJ, Humphreys EB, Mangold LA et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007 25 : 1765 1771
7. Pretlow TG, Pretlow TP, Yang B et al. Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer 1991 49 : 645 649
8. Magklara A, Scorilas A, Stephan C et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 2000 56 : 527 532
9. Aihara M, Lebovitz RM, Wheeler TM, Kinner BM, Ohori M, Scardino PT. Prostate specific antigen and Gleason grade: an immunohistochemical study of prostate cancer. J Urol 1994 151 : 1558 1564 (Pubitemid 24151302)
10. Epstein JI, Eggleston JC. Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: prognostic implications. Hum Pathol 1984 15 : 853 859
11. Oefelein MG, Smith N, Carter M, Dalton D, Schaeffer A. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J Urol 1995 154 : 2128 2131
12. Leibovici D, Spiess PE, Agarwal PK et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007 109 : 198 204
13. Myers RP. The Surgical Management of Prostate Cancer: Radical Retropubic and Radical Perineal Prostatectomy, 1st edn.
14. Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 2005 174 : 2191 2196
15. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001 165 : 1146 1151
16. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001 76 : 576 581
17. Sengupta S, Amling C, D'Amico AV, Blute ML. Prostate specific antigen kinetics in the management of prostate cancer. J Urol 2008 179 : 821 826
18. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003 95 : 1376 1383
19. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 294 : 433 439
20. Sengupta S, Slezak JM, Blute ML et al. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer 2006 106 : 2630 2635
21. Rodriguez-Covarrubias F, Larre S, De La Taille A, Abbou CC, Salomon L. The outcome of patients with pathological Gleason score > or =8 prostate cancer after radical prostatectomy. BJU Int 2008 101 : 305 307
22. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int 2008 101 : 299 304
23. Zhang H, Melamed J, Wei P et al. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun 2003 3 : 2
24. Perez-Martinez FC, Alonso V, Sarasa JL et al. Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand. J Clin Pathol 2007 60 : 290 294
25. Lexander H, Palmberg C, Hellman U et al. Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics 2006 6 : 4370 4380
26. Xie W, Nakabayashi M, Regan MM, Oh WK. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Cancer 2007 110 : 2709 2715
27. Thompson J, Hyytinen ER, Haapala K et al. Androgen receptor mutations in high-grade prostate cancer before hormonal therapy. Lab Invest 2003 83 : 1709 1713 (Pubitemid 38018533)
28. Babaian RJ, Camps JL, Frangos DN et al. Monoclonal prostate-specific antigen in untreated prostate cancer. Relationship to clinical stage and grade. Cancer 1991 67 : 2200 2206
29. Stein BS, Vangore S, Petersen RO. Immunoperoxidase localization of prostatic antigens. Comparison of primary and metastatic sites. Urology 1984 24 : 146 152
30. Greskovich FJ 3rd, Johnson DE, Tenney DM, Stephenson RA. Prostate specific antigen in patients with clinical stage C prostate cancer: relation to lymph node status and grade. J Urol 1991 145 : 798 801
31. Vollmer RT, Egawa S, Kuwao S, Baba S. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. Cancer 2002 94 : 1692 1698
32. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993 71 : 2031 2040